Navigation Links
Lorillard Tobacco Company Comments on Harvard School of Public Health Report

GREENSBORO, N.C., July 16 /PRNewswire/ -- While Lorillard Tobacco Company (a wholly-owned subsidiary of Lorillard, Inc. (NYSE: LO)) has not yet had the opportunity to fully review the latest report from the Harvard School of Public Health, the company is gratified that the report reaffirms its view with respect to the present state of the science examining menthol use in cigarettes, including that:

-- "The available [scientific] evidence remains inconclusive" that menthol cigarettes confer a higher risk than non-mentholated cigarettes for smoking-related diseases.

-- "Recent studies did not find significant differences in risk for disease between menthol and non-menthol smokers."

-- "Research on differences in cessation outcomes between menthol and non-menthol smokers had conflicting results."

However the report's conclusion that Lorillard controls or alters the menthol levels in its products to promote smoking initiation or addiction is categorically false.

Lorillard does not control levels of menthol to promote smoking among adolescents and young adults. Furthermore, Lorillard does not engineer any of its cigarettes to promote smoking initiation or nicotine addiction. Importantly, the target menthol specifications for Newport have not changed at all since 2000.

Lorillard is in the business of manufacturing cigarettes for sale to adult smokers. The company wants every adult smoker who prefers menthol cigarettes to choose its Newport product. This is why Lorillard strives to make a product with superior taste and consistency.

The company also rejects the report's conclusion that Lorillard targets youth smokers. The authors should know that pursuant to an agreement with the state's Attorneys General, Lorillard does not advertise in magazines that have a youth readership of 15 percent or greater and/or a circulation of two million or more readers under 18 years of age. This is not a new policy and has been in effect for years. Contrary to the report's assertion, while the magazine advertising expenditures for Newport may fluctuate from year to year, overall spending on magazine advertising has decreased over the last 10 years.

About Lorillard, Inc.

Lorillard, Inc. (NYSE: LO), the parent company of Lorillard Tobacco Company, is the third largest manufacturer of cigarettes in the United States. Lorillard was founded in 1760, and is the oldest continuously operating tobacco company in the U.S. Newport(R), Lorillard's flagship brand, is a menthol-flavored premium cigarette brand and the top selling menthol and second largest selling cigarette in the U.S. In addition to Newport, the

Lorillard product line has five additional brand families marketed under the Kent(R), True(R), Maverick(R), Old Gold(R) and Max(R) brand names. These six brands include 44 different product offerings which vary in price, taste, flavor, length and packaging. Lorillard's manufactures all of its products at its Greensboro, North Carolina facility and maintains its headquarters there.

Forward-Looking Statements

Certain statements made in this press release are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, or the Reform Act. Forward-looking statements include, without limitation, any statement that may project, indicate or imply future results, events, performance or achievements, and may contain the words "expect", "intend", "plan", "anticipate", "estimate", "believe", "will be", "will continue", "will likely result", and similar expressions. In addition, any statement that may be provided by management concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible actions by Lorillard, Inc. are also forward-looking statements as defined by the Reform Act.

Forward-looking statements are based on current expectations and projections about future events and are inherently subject to a variety of risks and uncertainties, many of which are beyond the control of Lorillard, Inc., that could cause actual results to differ materially from those anticipated or projected. Information describing factors that could cause actual results to differ materially from those in forward-looking statements is available in Lorillard, Inc.'s filings with the Securities and Exchange Commission. These filings are available from the SEC over the Internet or in hard copy, and are, in some cases, available from Lorillard, Inc. as well. Forward-looking statements speak only as of the time they are made, and Lorillard, Inc. expressly disclaims any obligation or undertaking to update these statements to reflect any change in expectations or beliefs or any change in events, conditions or circumstances on which any forward-looking statement is based.


Michael W. Robinson


SOURCE Lorillard Tobacco Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement from Lorillard Tobacco on FDA-Tobacco Regulation Legislation
2. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
3. Smokeless Tobacco Products Do Raise Cancer Risk
4. Grandmother is Inspiration for Winner of Tobacco Free Florida YouCare Contest
5. Rivalry Aside, Marlins and Rays Team Up To Fight Tobacco
6. Major Associations Band Together to Urge Congressional Action on Tobacco Legislation
7. Smokeless Tobacco: Not a Harmless Substitute
8. World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives
9. PA State Health Officials Encourage Smokers to Quit on World No Tobacco Day
10. A new way to look at lung cancer and tobacco carcinogens
11. World No Tobacco Day: Global Organizations Join Forces To Break the Tobacco Marketing Net and Help Children Grow Up Smoke-Free
Post Your Comments:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology: